ISSN:
1573-0646
Keywords:
deoxydoxorubicin (DXDX)
;
non-small cell carcinoma (NSCC)
;
phase II trials
;
Eastern Cooperative Oncology Group (ECOG)
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary A phase II trial of 4′ Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four responses, all partial, were observed in 35 evaluable patients, for a response rate of 11% (95% confidence limits 3.2% and 26.7%). Myelosuppression was the dose-limiting toxicity. Cardiotoxicity was not seen. DXDX has minimal activity against non-small cell lung cancer as a single agent at the dosage used in this study.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00216932
Permalink